“Lung cancer carries a substantial symptom burden, and a study published in Clinical Lung Cancer found that physical and emotional functioning scores within quality-of-life (QOL) questionnaires at diagnosis may help predict survival in patients with lung cancer.”
Standard Treatment May Not Be Best for Exon 20-Mutant Lung Cancer
“Rybrevant (amivantamab-vmjw) outperformed other therapies for the treatment of patients with exon 20 insertion-mutant, advanced non-small cell lung cancer (NSCLC), according to recent research presented at the 2023 European Lung Cancer Congress in Denmark.”
Cemiplimab Shows Clinical Benefit for Patients With PD-L1+ NSCLC and Brain Metastases
“A long-term exploratory analysis of the phase 3 EMPOWER Lung 1 trial (NCT03088540) demonstrated that patients with PD-L1–positive non–small cell lung cancer (NSCLC) that has metastasized to the brain may derive improvements in overall survival (OS) and progression-free survival (PFS) with frontline cemiplimab-rwlc (Libtayo) compared with chemotherapy.”
Adagrasib Garners 68% ORR in Patients With KRAS G12C-Mutated Non–Small Cell Lung Cancer
“Patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC) who achieved at least 90% mutation allele frequency clearance (MAFC) experienced high overall response rates following treatment with adagrasib (Krazati), according to findings from an exploratory analysis of KRAS G12C–mutant circulating tumor DNA (ctDNA) from the registrational phase 2 KRYSTAL-1 trial (NCT03785249).”
The Multidisciplinary Team: Bringing Their A-Game to Lung Cancer Care
“Collaboration and alliance: Those are two key concepts behind the multidisciplinary team (MDT) to fully manage patients with lung cancer. But what happens when collaboration gets curtailed and alliances get annulled? Researchers in Italy sought to answer that question with an interdisciplinary analysis with risk management activities in MDT for lung cancer.”
Taletrectinib Sustains Positive Efficacy and Safety in ROS1-Positive NSCLC
“Taletrectinib (DS-6051b/AB-106) continued to demonstrate clinically meaningful efficacy and favorable a safety profile in patients with ROS1-positive non–small cell lung cancer (NSCLC), according to updated efficacy and safety data from the phase 2 TRUST-I trial (NCT04395677).”
Olanzapine to Prevent Chemotherapy-Related Anorexia in Newly Diagnosed Patients With Advanced Cancers
“In an Indian single-center study reported in the Journal of Clinical Oncology, Sandhya et al found that olanzapine was associated with weight gain and improved appetite vs placebo in patients receiving chemotherapy for newly diagnosed locally advanced or metastatic gastric, hepatopancreaticobiliary, or lung cancers.”
TSET funds mobile lung cancer screening
“OKLAHOMA CITY – OU Health Stephenson Cancer Center at the University of Oklahoma Health Sciences Center has received more than $1.7 million from the state’s Tobacco Settlement Endowment Trust to increase access to lung cancer screening across the state.”
‘A Million Data Points’: A 30-Year Long Lung Cancer Study Meets AI
“This is the Boston Lung Cancer Study, a long-running study of lung cancer patients that analyzes the disease’s genetic and environmental risk factors. But in recent years, the study reached a new frontier in medicine. The Harvard Artificial Intelligence in Medicine program has begun analyzing the dataset in unprecedented ways — by using artificial intelligence.”
